BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

National Institute for Clinical Excellence (NICE) Reverses Earlier Decision, Backs Johnson & Johnson (JNJ)'s Zytiga


5/16/2012 7:15:47 AM

Britain's drug watchdog has reversed a controversial decision not to fund a new prostate cancer pill that was developed in the country after maker Johnson & Johnson agreed a new discount on supplies to the UK state healthcare service. Zytiga, which is known chemically as abiraterone, was approved last year in Europe and the United States to treat advanced prostate cancer in patients who previously received chemotherapy. The drug was developed by researchers at the Institute of Cancer Research and London's Royal Marsden Hospital. British pharmaceutical firm BTG is entitled to receive royalty payments on the drug.

Read at Reuters
Read at News Release
Read at Wall Street Journal


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->